Nanosonics Highlights Growth and Expanding Portfolio in FY26 Half-Year Update

An announcement from Nanosonics Limited ( (AU:NAN) ) is now available.

Nanosonics has presented its FY26 half-year results, highlighting continued growth in its installed base to 38,080 units and reinforcing its position in ultrasound probe reprocessing through the trophon platform. The company is also progressing the phased commercialisation of its CORIS system for endoscope reprocessing, which underscores its strategy to broaden its infection prevention portfolio and could strengthen its competitive positioning and value proposition for healthcare providers focused on patient safety.

The most recent analyst rating on (AU:NAN) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.

More about Nanosonics Limited

Nanosonics Limited is a medical technology company specialising in transformative device reprocessing solutions that aim to improve patient safety and clinical outcomes. Its flagship trophon system holds a market-leading position in ultrasound probe reprocessing, and the company is expanding into endoscope reprocessing through its CORIS platform, targeting high standards of infection prevention in healthcare settings.

YTD Price Performance: -5.04%

Average Trading Volume: 411,916

Technical Sentiment Signal: Sell

Current Market Cap: A$1.09B

For an in-depth examination of NAN stock, go to TipRanks’ Overview page.